Success Metrics

Completion Rate
0%(0/4)
Active Trials
0(0%)
Terminated
4(80%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
2
40%
Ph phase_3
2
40%

Phase Distribution

2

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 5 finished

Non-Completion Rate

100.0%

5 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Terminated(5)

Detailed Status

Terminated4
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)

Trials by Status

terminated480%
withdrawn120%

Recent Activity

0 active trials
Showing 5 of 5
withdrawnphase_1

Drug Interaction Between Ritonavir And Sitaxsentan

NCT01251848
terminatedphase_2

Study on the Effects of Sitaxsentan on Airway Remodeling in Patients With Severe Asthma

NCT01050491
terminatedphase_1

A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses

NCT01244620
terminatedphase_3

Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients

NCT01210443
terminatedphase_3

A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients

NCT01204853

Clinical Trials (5)

Showing 5 of 5 trials
NCT01251848Phase 1

Drug Interaction Between Ritonavir And Sitaxsentan

Withdrawn
NCT01050491Phase 2

Study on the Effects of Sitaxsentan on Airway Remodeling in Patients With Severe Asthma

Terminated
NCT01244620Phase 1

A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses

Terminated
NCT01210443Phase 3

Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients

Terminated
NCT01204853Phase 3

A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5